Importance of Patient Listening in The Development of Rare Disease Treatments @checkrare
Importance of Patient Listening in The Development of Rare Disease Treatments  @checkrare
Uploaded August 2026 | Updated November 2026, 3 hours ago
Matt Trudeau, President of ITF Therapeutics, discusses the importance of patient listening in the development of Duvyzat (givinostat) for Duchenne muscular dystrophy (DMD).

DMD is a rare genetic, neuromuscular condition characterized by progressive muscle wasting. Symptoms include progressive weakness and atrophy of both skeletal and heart muscle. Early signs may include delayed ability to sit, stand, or walk and difficulties learning to speak. DMD is caused by genetic changes in the DMD gene.

Just ahead of the second anniversary of its commercial launch, ITF Therapeutics’ givinostat was prescribed to its 2,000th patient in the US. Givinostat is a histone deacetylase (HDAC) inhibitor approved for patients ages six and older with DMD.

Mr. Trudeau highlights the importance of earning trust in the rare disease community, something he explains starts with listening to patients and patient advocates. From attending patient conferences to hiring patient advocacy roles and meeting with advocacy organizations, ITF Therapeutics strives to keep patients at the forefront of their treatment development process.

Improving communication with patients, developing effective educational tools, and removing non-clinical barriers while improving accessibility are other initiatives that Mr. Trudeau deems crucial.

While there is still work to be done in DMD, other indications currently in the pipeline for givinostat include Becker muscular dystrophy and polycythemia vera.

CHAPTERS
Introduction 00:00
DMD Overview 00:34
Development of Givinostat 1:33
Lessons Learned Since Launch 3:19
Other Indications in the Pipeline 7:03
Take Home Message 8:42
Importance of Patient Listening in The Development of Rare Disease TreatmentsENERGY Clinical Trial Testing Imaavy (Nipocalimab) in Warm Autoimmune Hemolytic Anemia (wAIHA)What to Expect: 2026 MGFA Scientific SessionBurdensome Symptoms in Fabry DiseasePlasma Proteomics May Predict Disease Manifestations in ALSFirst-Line Therapy Approved for Rare Lung Cancer  | The CheckRare Brief Ep 72-Year Data on Crinecerfont for the Treatment of Patients With Congenital Adrenal HyperplasiaRare Endocrine Exchange: Why This Conversation MattersBeyond AChR: Recognizing and Treating MuSK Ab+, LRP4, Ab+ and Triple Seronegative Myasthenia GravisNew Huntingtons Disease Gene Therapy Application | The CheckRare Brief Ep 6New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | Ep 5FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome
CheckRare |

Importance of Patient Listening in The Development of Rare Disease Treatments

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER